



## AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

### In the claims:

Please amend claims 1, 8, 9, 11, 37, 38 and 39 as follows.

C/ 1. (Twice Amended) A method for providing dopamine or a dopamine precursor to a subject with schizophrenia, comprising administering a cell/support complex to the prefrontal cortex of the subject's brain, wherein said cell/support complex comprises cells adhered to a support matrix, wherein said cells produce dopamine or a dopamine precursor and wherein said cell/support complex is administered in an amount effective to alleviate a negative symptom of schizophrenia.

2. The method of claim 1, wherein said cell/support complex is administered to the subject by injection.

3. The method of claim 1, wherein said cell/support complex is administered to the subject by implantation.

4. The method of claim 1 wherein said support matrix is made of material selected from the group consisting of glass, polystyrene, polypropylene, polyethylene, polyvinylidene fluoride, polyurethane, polyalginate, polysulphone, polyvinyl alcohol, acrylonitrile polymers, polyacrylamide, polycarbonate, polypentene, polypentane, acrylonitrile polymer, nylon, magnetite, natural polysaccharide, modified polysaccharide, collagen, gelatin and modified gelatin.

5. The method of claim 4, wherein said support matrix is gelatin or modified gelatin.

6. The method of claim 5 wherein said support matrix is crosslinked gelatin.

---

C2 8. (Twice Amended) The method of claim 1, wherein the cells are selected from the group consisting of retinal pigment epithelial cells, chromaffin cells, cells of neural origin, paraneural cells, cells engineered by somatic cell hybridization, cells derived from the adrenal medulla, and cells that have been genetically engineered to express dopamine or a dopamine precursor.

---

9. (Amended) The method of claim 8 wherein the cells produce a dopamine precursor.

10. The method of claim 8 wherein the cells produce dopamine.

---

C3 11. (Twice Amended) The method according to claim 8 wherein the cells are retinal pigment epithelium (RPE) cells.

---

12. The method of claim 1 wherein the subject is a human.

13. The method of claim 1 wherein said cell/support complex further comprises protective cells.

14. The method of claim 13 wherein said cell/support complex further comprises support cells.

15. The method of claim 1 wherein said cell/support complex further comprises protective cells adherent to a support matrix.

16. The method of claim 15 wherein said cell/support complex further comprises support cells adherent to a support matrix.

17. The method of claim 1 wherein the negative symptom is selected from the group consisting of affective flattening, alogia, avolition, anhedonia, social withdrawal, and apathy.

C4 37. (Twice Amended) A pharmaceutical composition comprising therapeutic cells and Sertoli cells, wherein the therapeutic cells and the Sertoli cells are adhered to a support matrix.

38. (Twice Amended) A pharmaceutical composition comprising therapeutic cells, protective cells and support cells, wherein the therapeutic cells, protective cells and support cells are adhered to a support matrix.

39. (Twice Amended) A kit suitable for use in providing dopamine or a dopamine precursor to a subject with schizophrenia, comprising in a suitable packaging:  
therapeutic cells that produce dopamine or a dopamine precursor;  
protective cells;  
support cells; and  
a support matrix, wherein the therapeutic cells, protective cells and support cells can be adhered to the support matrix.

40. The kit according to claim 39 wherein the cells and the support matrix are each contained in separate containers.